What is the official ID of this bill?

The official print number for this legislation is S 1133.

When did the legislative process begin?

The process officially started on 2023-03-30.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/118/bills/s1133/BILLS-118s1133is.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

Who is the primary sponsor?

The primary sponsor is Sen. Braun, Mike [R-IN].

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Analysis and Potential Impact of S 1133

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Increased Oversight of Drug Discount Savings Use in 340B Program.

Q: What are the main provisions?

Key points include: Covered entities must allow audits to determine how they use the net income derived from discounted drug purchases. Increased transparency aims to prevent misuse of funds and ensure that 340B program savings benefit patients. Entities are required to retain and provide records necessary for carrying out these audits.

This bill introduces new transparency rules for healthcare facilities participating in the 340B drug discount program. These facilities must now permit audits to determine how they use the financial savings generated from purchasing discounted drugs. The goal is to ensure that these funds are dedicated to improving patient care, rather than being diverted elsewhere.

Key points

Covered entities must allow audits to determine how they use the net income derived from discounted drug purchases.

Increased transparency aims to prevent misuse of funds and ensure that 340B program savings benefit patients.

Entities are required to retain and provide records necessary for carrying out these audits.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

340B Accountability Act of 2023

Print number: S 1133

Sponsor: Sen. Braun, Mike [R-IN]

Process start date: 2023-03-30

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-09-2025

Source data: api.congress.gov

AI work logs for this document launch

Increased Oversight of Drug Discount Savings Use in 340B Program.

Key Questions about Increased Oversight of Drug Discount Savings Use in 340B Program.